Cargando…

Effect of ALDH1A1 Gene Knockout on Drug Resistance in Paclitaxel and Topotecan Resistant Human Ovarian Cancer Cell Lines in 2D and 3D Model

Ovarian cancer is the most common cause of gynecological cancer death. Cancer Stem Cells (CSCs) characterized by drug transporters and extracellular matrix (ECM) molecules expression are responsible for drug resistance development. The goal of our study was to examine the role of aldehyde dehydrogen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowacka, Marta, Ginter-Matuszewska, Barbara, Świerczewska, Monika, Sterzyńska, Karolina, Nowicki, Michał, Januchowski, Radosław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950618/ https://www.ncbi.nlm.nih.gov/pubmed/35328460 http://dx.doi.org/10.3390/ijms23063036

Ejemplares similares

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations
por: Świerczewska, Monika, et al.
Publicado: (2019)

Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell Lines
por: Januchowski, Radosław, et al.
Publicado: (2016)

The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines
por: Kazmierczak, Dominika, et al.
Publicado: (2020)

Piperine Targets Different Drug Resistance Mechanisms in Human Ovarian Cancer Cell Lines Leading to Increased Sensitivity to Cytotoxic Drugs
por: Wojtowicz, Karolina, et al.
Publicado: (2021)

Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2019)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines
por: Kazmierczak, Dominika, et al.
Publicado: (2022)

The significance of lumican expression in ovarian cancer drug-resistant cell lines
por: Klejewski, Andrzej, et al.
Publicado: (2017)

New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines
por: Świerczewska, Monika, et al.
Publicado: (2017)

Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines
por: Januchowski, Radosław, et al.
Publicado: (2017)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines
por: Stasiak, Piotr, et al.
Publicado: (2022)

Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines
por: Januchowski, Radosław, et al.
Publicado: (2016)

New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines
por: Świerczewska, Monika, et al.
Publicado: (2018)

Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
por: Vukovic, V., et al.
Publicado: (1997)

Prediction of steroid resistance and steroid dependence in nephrotic syndrome children
por: Zaorska, Katarzyna, et al.
Publicado: (2021)

The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients
por: Izycka, Natalia, et al.
Publicado: (2023)

MDR Gene Expression Analysis of Six Drug-Resistant Ovarian Cancer Cell Lines
por: Januchowski, Radosław, et al.
Publicado: (2013)

Extracellular Matrix Proteins Expression Profiling in Chemoresistant Variants of the A2780 Ovarian Cancer Cell Line
por: Januchowski, Radosław, et al.
Publicado: (2014)

Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor
por: Dyrkheeva, Nadezhda S., et al.
Publicado: (2023)

ALDH(2) knockout protects against aortic dissection
por: Luo, Chentao, et al.
Publicado: (2022)

ALDH-Dependent Glycolytic Activation Mediates Stemness and Paclitaxel Resistance in Patient-Derived Spheroid Models of Uterine Endometrial Cancer
por: Mori, Yutaro, et al.
Publicado: (2019)

An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer
por: Wang, Wenjing, et al.
Publicado: (2022)

Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan
por: Rosa-Teijeiro, Chloé, et al.
Publicado: (2021)

ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism
por: Yue, Hanxun, et al.
Publicado: (2022)

The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells
por: Wantoch von Rekowski, Kathleen, et al.
Publicado: (2019)

Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells
por: Croker, Alysha K., et al.
Publicado: (2017)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Sex-Specific Metabolic Effects of Dietary Folate Withdrawal in Wild-Type and Aldh1l1 Knockout Mice
por: Sharma, Jaspreet, et al.
Publicado: (2022)

The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan
por: Gasimli, Khayal, et al.
Publicado: (2022)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
por: Tewari, Krishnansu S., et al.
Publicado: (2023)

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
por: Vanhoefer, U, et al.
Publicado: (1999)

Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2020)

How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance
por: Ciccone, Valerio, et al.
Publicado: (2020)

Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies
por: Wantoch von Rekowski, Kathleen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7jsq6akfhfeee74fjvql9t79kd